论文部分内容阅读
目的:分析不同剂量瑞舒伐他汀钙治疗冠心病合并高脂血症患者的临床效果以及对患者血清hs-CRP和颈动脉内膜中层厚度(IMT)的影响。方法:选择2013年6月-2015年6月在我院接受治疗的冠心病合并高脂血症患者203例,根据用药剂量不同将其分为小剂量组(70例)、中剂量组(64例)及大剂量组(69例),分别采用口服瑞舒伐他汀钙5 mg/次/日、10 mg/次/日和20 mg/次/日进行治疗。观察并比较三组患者治疗前后血脂(TG,TC,LDL-C,HDL-C)、血清hs-CRP及IMT的变化情况。结果:治疗前,三组患者血清hs-CRP,TG,TC,LDL-C,HDL-C以及IMT值比较,差别均无统计学意义(P>0.05);治疗后,三组患者血清hs-CRP,TG,TC,LDL-C,HDL-C以及IMT值均较治疗前降低,差异具有统计学意义(P<0.05);大剂量瑞舒伐他汀钙组患者血清hs-CRP,TG,TC,LDL-C,HDL-C以及IMT值显著低于中剂量组和小剂量组,差异具有统计学意义(P<0.05);中剂量组患者血清hs-CRP,TG,TC,LDL-C,HDL-C以及IMT值显著低于小剂量组,差异具有统计学意义(P<0.05)。结论:瑞舒伐他汀钙能够改善冠心病合并高脂血症患者的血脂水平、降低血清hs-CRP及IMT,并且其疗效与药物剂量存在量效关系。
OBJECTIVE: To analyze the clinical effects of different doses of rosuvastatin calcium on patients with coronary heart disease complicated with hyperlipidemia and its effect on serum hs-CRP and carotid artery intima-media thickness (IMT). Methods: Totally 203 patients with coronary heart disease and hyperlipidemia who were treated in our hospital from June 2013 to June 2015 were divided into two groups: low dose group (70 cases) and middle dose group (64 cases) Cases) and high dose group (69 cases) were treated with oral rosuvastatin calcium 5 mg / time / day, 10 mg / time and 20 mg / time / day for treatment. The changes of serum lipids (TG, TC, LDL-C, HDL-C), serum hs-CRP and IMT before and after treatment were observed and compared between the three groups. Results: Before treatment, there was no significant difference in serum hs-CRP, TG, TC, LDL-C, HDL-C and IMT between the three groups (P> 0.05) CRP, TG, TC, LDL-C, HDL-C and IMT were lower than before treatment, the difference was statistically significant (P <0.05); high-dose rosuvastatin calcium group serum hs-CRP, TG, TC , LDL-C, HDL-C and IMT were significantly lower than the middle dose group and low dose group, the difference was statistically significant (P <0.05); serum hs-CRP, TG, TC, LDL-C, HDL-C and IMT values were significantly lower than the low-dose group, the difference was statistically significant (P <0.05). Conclusion: Rosuvastatin calcium can improve the blood lipid level, reduce the serum hs-CRP and IMT in patients with coronary heart disease complicated with hyperlipidemia, and its efficacy is related to the dose-effect relationship.